Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;20(6):237.
doi: 10.3892/etm.2020.9367. Epub 2020 Oct 21.

Direct oral anticoagulant treatment of deep vein thrombosis reduces IL-6 expression in peripheral mono-nuclear blood cells

Saverio Candido  1   2 , Giovanni Lumera  3   4 , Giuliana Barcellona  3   4 , Davide Vetri  3   4 , Elda Tumino  3   4 , Ingrid Platania  3   4 , Evelise Frazzetto  3   4 , Graziella Privitera  3   4 , Carmela Incognito  4 , Agostino Gaudio  3 , Salvatore Santo Signorelli  3   4
Affiliations

Direct oral anticoagulant treatment of deep vein thrombosis reduces IL-6 expression in peripheral mono-nuclear blood cells

Saverio Candido et al. Exp Ther Med. 2020 Dec.

Abstract

Multiple factors play a pathophysiologic role for the venous thromboembolism (VTE) as a multi-factorial disease. Inflammation might play a peculiar role in shifting towards a pro-thrombotic state. Anticoagulant drugs are the first cure line for VTE. The low-molecular-weight heparins (LMWH) show anti-coagulant capability as well as reducing levels of inflammatory factors, including interleukin (IL)-6. The direct oral anticoagulants (DOACs) have shown efficacy in threating VTE, additionally to the anti-activated factor X these drugs seem able to reduce the abnormal release of pro-inflammatory agents. The present study evaluated the capability of DOACs in reducing plasma level of IL-6 in patients suffered from deep vein thrombosis (DVT) of the lower limbs. Our results showed reduced IL-6 expression levels in the peripheral lymphocytes of DVT compared to controls (fold-change, 2.8; P<0.05). We postulate that lowered IL-6 expression in the lymphocytes of DVT patients may mediate the anti-inflammatory action of DOACs. The present study is the first evidence concerning the anti-inflammatory properties of DOACs in specific setting of VTE patients such as DVT.

Keywords: deep vein thrombosis; direct oral anti-coagulant; inflammation; interleukin-6; therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expression levels of IL-6 in DVT samples and CTRL. IL, interleukin; DVT, deep vein thrombosis; CTRL, control
See this image and copyright information in PMC

References

    1. Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest. 2012;122:2331–2336. doi: 10.1172/JCI60229. - DOI - PMC - PubMed
    1. Branchford BR, Carpenter SL. The role of inflammation in venous thromboembolism. Front Pediatr. 2018;6(142) doi: 10.3389/fped.2018.00142. - DOI - PMC - PubMed
    1. Riva N, Donadini MP, Ageno W. Epidemiology and pathophysiology of venous thromboembolism: Similarities with atherothrombosis and the role of inflammation. Thromb Haemost. 2015;113:1176–1183. doi: 10.1160/TH14-06-0563. - DOI - PubMed
    1. Prandoni P. Links between arterial and venous disease. J Intern Med. 2007;262:341–350. doi: 10.1111/j.1365-2796.2007.01815.x. - DOI - PubMed
    1. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006;367:1075–1079. doi: 10.1016/S0140-6736(06)68474-2. - DOI - PubMed

LinkOut - more resources